Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results

Written by Customer Service on January 10, 2021. Posted in Public Companies.

Record Testing Revenue, Adopters and AVISE CTD® VolumesSAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported preliminary, unaudited financial results for the quarter ended December 31, 2020.Testing revenue for the three months ended December 31, 2020 is expected to be between approximately $10.5 million and $10.8 million, an increase of 11% and 15% compared with $9.5 million in the third quarter of 2020, and an increase of 10% to 13% compared with $9.6 million in the fourth quarter of 2019. Exagen delivered a total of approximately 28,600 AVISE CTD tests, including AVISE Lupus, in the quarter, with 1,690 ordering healthcare providers, a record number of 635 adopters and a sequential quarterly...

Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference

Written by Customer Service on January 10, 2021. Posted in Public Companies.

SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:H.C. WAINWRIGHT BIOCONNECT 2021 January 11-14, 2021 (Virtual Conference)Sorrento’s Corporate Presentation will be available on-demand for 90 days starting on Monday, January 11, 2021 at 6:00 AM (Eastern Standard Time) at the following link:https://journey.ct.events/view/e4fa6fec-c4ca-4768-9dfa-374369929341An updated corporate presentation will also be available at www.sorrentotherapeutics.com.About Sorrento Therapeutics, Inc. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento’s multimodal, multipronged approach to fighting cancer is made...

Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

Written by Customer Service on January 10, 2021. Posted in Public Companies.

– In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 –– Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 –WALTHAM, Mass., Jan. 10, 2021 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data from its myotonic dystrophy type 1 (DM1) program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease.Dyne’s FORCE™ platform leverages the importance of transferrin 1 receptor, TfR1, in muscle biology as the foundation for its novel approach. TfR1, which is highly expressed on the...

SAGA PURE – RESOLUTION TO INCREASE THE SHARE CAPITAL INCREASE IN CONNECTION WITH SUBSEQUENT OFFERINGS

Written by Customer Service on January 10, 2021. Posted in Public Companies.

Oslo, 10 January 2021Reference is made to the stock exchange announcement on 30 December 2020 regarding information on three subsequent offerings in Saga Pure ASA (“Saga” or the “Company“). The board of directors of Saga has today, 10 January 2021, pursuant to the authorisation granted to it by the extraordinary general meeting held on 10 November 2020, resolved to increase the share capital by up to a total of NOK 137,000 through issuance of up to a total of 13,700,000 new shares, each with a par value of NOK 0.01, in connection with subsequent offerings in the Company.The share capital increases have been resolved to carry out; (i) a subsequent offering following the private placement completed on 14 December 2020 (“Subsequent Offering I“), (ii) a subsequent offering following the private placement...

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

Written by Customer Service on January 10, 2021. Posted in Public Companies.

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-yearReports preliminary 2020 total revenues of $1.55 billion at the midpoint and Adjusted EBITDA of $635 million at the midpoint, both at or above prior guidance given in November 2020GAITHERSBURG, Md., Jan. 10, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.“In a year full of unprecedented challenges due to the pandemic, the Emergent team’s unwavering commitment produced incredible results,” said Robert G. Kramer, president and chief executive officer. “Operationally, we rapidly responded to our customers’...

Medigus Announces Proposed Underwritten Public Offering of American Depositary Shares

Written by Customer Service on January 10, 2021. Posted in Public Companies.

OMER, Israel, Jan. 10, 2021 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq, TASE: MDGS) (the “Company” or “Medigus”), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that it intends to offer its American Depositary Shares (“ADSs”) for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter an option to purchase an additional 15 percent of the ADSs offered in the public offering solely to cover over-allotments, if any, exercisable until the earlier of 30-days or the last day of trading of the Company’s ordinary shares on the Tel-Aviv Stock Exchange prior to their delisting. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The offering is subject to market conditions,...

Day: January 10, 2021